September 2022 Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model antibody atezolizumab and nab-paclitaxel has shown clinical activity in advanced TNBC with PD-L1-positive tumor-infiltrating As tumor-associated macrophages (TAMs) serve as major contributors to the immuno-suppressive tumor microenvironment We show that through proper calibration, the model captures the macrophage heterogeneity in the tumor

and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors

October 2022 "Pepducins are small-lipidated peptides designed from the intracellular loops of G protein-coupled receptors (GPCRs) that act in an allosteric manner to modulate the activity of GPCRs. Over the past 2 decades, pepducins have progressed initially from pharmacologic tools used to manipulate GPCR activity in an orthosteric site-independent manner to compounds with therapeutic potential that have even been used safely in phase 1 and 2 clinical trials in human subjects. The effect of pepducins at their cognate receptors has been shown to vary between antagonist, partial agonist, and biased agonist outcomes in various primary and clonal cell systems, with even small changes in amino acid sequence altering these properties and their receptor selectivity. To date, pepducins designed from numerous GPCRs have been studied for their impact on pathologic conditions, including cardiovascular diseases such as thrombosis, myocardial infarction, and atherosclerosis. This review will focus in particular on pepducins designed from protease-activated receptors, C-X-C motif chemokine receptors, formyl peptide receptors, and the β2-adrenergic receptor. We will discuss the historic context of pepducin development for each receptor, as well as the structural, signaling, pathophysiologic consequences, and therapeutic potential for each pepducin class." Read more at the source #DrGPCR #GPCR #IndustryNews

solid tumors for first-in-child use of PRL3-zumab humanized antibody Published date September 21, 2023 However, its physiological expression in pediatric embryonal and mesenchymal tumors and its association We sought to profile the expression of PRL3 in pediatric tumors in relation to survival outcomes, expression Among 64 pediatric tumors, PRL3 was most frequently expressed in neuroblastoma (100%), rhabdomyosarcoma , neuroblastoma , non-rhabdomyosarcoma soft tissue sarcoma , osteosarcoma , pediatric tumors , rhabdomyosarcoma

Trabecular Identity Abhishek Kumar Singh Investigating The Role of ADGRB3 Loss of Expression in Brain Tumor These observations lead me to hypothesize that ADGRB3 functions as a tumor suppressor in the brain, and tumor)." brain tumors. Standard of care for MB includes tumor resection, chemotherapy, and cranio-spinal radiation.

in tumor progression Published date July 31, 2024 Abstract "G protein-coupled receptors (GPCRs) are essential contributors to tumor growth and metastasis due to their roles in immune cell regulation. Here, we discuss the current understanding of the roles of GPCRs and their signaling pathways in tumor This expanded understanding of the role of GPCRs may shed light on the mechanisms underlying tumor progression Qiu, Bin Yu, Mei Ma Tags GPCRs , cancer immune checkpoints , cancer immunotherapy , immune cells , tumor